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Abstract
Changes in DNA methylation, whether hypo- or hypermethylation, have been shown to be associated with the
progression of colorectal cancer. Methylation changes substantially in the progression from normal mucosa to
adenoma and to carcinoma. This phenomenon has not been studied extensively and studies have been restricted
to individual CpG islands, rather than taking a whole-genome approach. We aimed to study genome-wide
methylation changes in colorectal cancer. We obtained 10 fresh-frozen normal tissue–cancer sample pairs,
and five fresh-frozen adenoma samples. These were run on the lllumina HumanMethylation27 whole-genome
methylation analysis system. Differential methylation between normal tissue, adenoma and carcinoma was
analysed using Bayesian regression modelling, gene set enrichment analysis (GSEA) and hierarchical clustering
(HC). The highest-rated individual gene for differential methylation in carcinomas versus normal tissue and
adenomas versus normal tissue was GRASP (padjusted = 1.59 × 10–5, BF = 12.62, padjusted = 1.68 × 10–6, BF =
14.53). The highest-rated gene when comparing carcinomas versus adenomas was ATM (padjusted = 2.0 × 10–4,
BF = 10.17). Hierarchical clustering demonstrated poor clustering by the CIMP criteria for methylation. GSEA
demonstrated methylation changes in the Netrin–DCC and SLIT–ROBO pathways. Widespread changes in DNA
methylation are seen in the transition from adenoma to carcinoma. The finding that GRASP, which encodes the
general receptor for phosphoinositide 1-associated scaffold protein, was differentially methylated in colorectal
cancer is interesting. This may be a potential biomarker for colorectal cancer.
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Introduction
Epigenetic modification of DNA has been increasingly
recognized as performing an important role in carcino-
genesis. However, there are surprisingly few studies of
genome-wide methylation and its effects in colorectal
cancer (CRC). Initial studies of gene-specific promoter
methylation [1] described the phenomenon of the CpG
island phenotype (CIMP), in which multiple tumour
suppressor genes, such as CDKN2A and MLH1 ,
were aberrantly methylated at their promoter regions.
CIMP tumours are known to have distinct clinical and
pathological characteristics. These include [2] high
rates of microsatellite instability (MSI) and BRAF
mutations, as well as being predominantly in the right
side of the colon.
Extensive work has been carried out to investigate
the characteristics of CIMP tumours. Ogino et al [2]
examined DNA methylation in five gene promoter
regions (CACNA1G , CDKN2A, CRABP1 , MLH1 and
NEUROG1 ) in a large set of 840 population-based col-
orectal cancer samples. They defined several types of
CIMP, including CIMP-low (1–3/5 promoter regions
methylated). CIMP-low tumours had significantly more
KRAS mutations as compared to other groups, CIMP-
high (≥ 4/5 promoter regions methylated) or CIMP-
negative (0/5 promoter regions methylated).
Nosho et al [3] verified these categories, also vali-
dating the finding that CIMP-high tumours were pre-
dominantly poorly differentiated, proximally located,
microsatellite unstable and frequently had BRAF muta-
tions. In examining CIMP-negative tumours, Ogino
et al [4] and Goel et al [5] found that tumours belong-
ing to this group frequently demonstrated loss of het-
erozygosity at 18q, indicating chromosomal instability
(CIN). This phenomenon and the associations observed
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with CIMP-low and CIMP-high tumours have been
reproduced independently by other groups [6–9].
Yagi et al [10] carried out methylated DNA
immunoprecipitation-on-chip (MeDIP-Chip) analysis
of HCT116 and SW480 CRC cell lines and coupled
this with whole-genome expression array analysis in
a set of primary CRCs. Although they demonstrated
some associations between low levels of CIMP and
KRAS mutation, their study had a very high level
of bias, due to the use of only two cell lines, with
potential bias due to methylation differences in cell
lines.
Ang et al [11] utilized an Illumina Goldengate
methylation array to examine the methylation status
of 1505 CpG islands. Examining fresh-frozen tissue
from 91 CRC samples against 28 randomly selected,
normal colorectal tissue samples, they found that
202 CpG islands were differentially methylated in
tumours. Their top four differentially methylated genes
– comparing methylation between tumour and normal
mucosa – were EYA4 , HS3ST2 , TFPI2 and SLIT2 .
Using unsupervized hierarchical clustering analysis,
they found that differential methylation segregated into
CIMP-H, -M and –L; however, their findings have not
been independently reproduced and their study may
have experienced bias due to small sample size.
Hinoue et al [12] analysed 120 tumour samples,
a minority of which were paired with corresponding
normal tissues, utilizing the Illumina HumanMethy-
lation27 platform. They described three biologically
distinct groups. The first, CIMP-H, showed a strong
association with hypermethylation of MLH1 and the
BRAF V600E mutation. The second, CIMP-L, was
enriched for KRAS mutations. In the third group, two
distinct subgroups were found, the first with a high
frequency of TP53 mutations and association with the
distal colon, and the second with low-level DNA hyper-
methylation and an association with the rectum. This
study was primarily geared towards analysis of patterns
of gene expression in relation to CpG island hyper-
methylation. A paired analysis of methylation was not
carried out, and no premalignant lesions were analysed.
Yamauchi et al [13] recently carried out a study
which examined the rates of CIMP, KRAS and BRAF
mutations and microsatellite instabilities (MSIs) com-
pared to the location of tumours in the colon or rec-
tum. They found that rates of CIMP, MSI and BRAF
mutation increased from the distal rectum towards the
proximal colon. They suggested that these changes
demonstrated that methylation occurs as a continuum in
the colon, rather than a simple proximal/distal tumour
divide, as previously described. They also found that
cecal tumours represented a unique subtype of colorec-
tal cancer, possessing high KRAS mutation frequency
but lower CIMP-high frequency than in ascending
colon tumours.
A further study by the Cancer Genome Atlas Net-
work [14] examined methylation patterns in 276 col-
orectal tumours as part of a larger study. Using unsu-
pervised hierarchical clustering, it found that tumours
segregated into four groups. The first two, CIMP-
high and CIMP-low, were identical to those previously
described. It additionally described two other groups,
which consisted of tumours that were not hypermethy-
lated but had a higher frequency of APC and TP53
mutations than the CIMP-high and -low groups.
We aimed to carry out a whole-genome methylation
analysis of paired CRC and normal tissue, as well as
colorectal adenomas to identify changes in patterns of
methylation in each of these lesions.
Materials and methods
Patient recruitment
Adenomas were sampled at Hammersmith Hospi-
tal from patients undergoing colonoscopy. CRCs and
paired normal tissues were from patients at St George’s
Hospital undergoing a resection of their tumours. The
clinical and pathological characteristics of the cancers
and adenomas are shown in Tables 1 and 2. At the
time of surgery, resection specimens were immediately
placed on ice and conveyed to a specialist histopatholo-
gist, where the specimen was opened and a representa-
tive sample of adenoma/cancer taken. For the cancers,
paired normal colonic mucosa was taken as far as pos-
sible from the site of the tumour. Prior to freezing,
confirmatory H&E-stained frozen sections were taken
to confirm that tumour or normal tissue was present.
The specimens were immediately snap-frozen in liquid
nitrogen and then stored at −80 ◦C until use. Ethi-
cal approval was obtained from Oxfordshire Research
Ethics Committee (MREC 05/Q1605/66).
DNA extraction and processing
DNA was extracted using proteinase K digestion at
55 ◦C over 2 days in 180 µl buffer ATL and was puri-
fied using a Qiagen DNEasy kit. DNA samples were
Table 1. Details of carcinomas
Tumour ID Age TNM stage Duke stage Site
20 T 85 T4N0M0 B Caecum
21 T 77 T2N2M1 D Rectum
22 T 85 T3N0M0 B2 Caecum
23 T 94 T2N0M0 B1 Rectum
24 T 84 T3N2MX C2 Sigmoid
26 T 51 T4N2MX C2 Rectum
27 T 66 T3N1M0 C2 Sigmoid
28 T 80 T4N0M0 B Descending colon
29 T 58 T3N0M0 B2 Sigmoid
30 T 48 T3N0M0 B2 Caecum
Table 2. Details of adenomas
ID Age Dysplasia Location Morphology
Ad1 74 Severe Rectum Tubulovillous
Ad2 64 Mild Colon Tubulovillous
Ad3 84 Moderate Colon Tubulovillous
Ad4 84 Moderate Colon Tubulovillous
Ad5 54 Moderate Colon Tubulovillous
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quantified using spectrophotometry. DNA samples
were diluted to 50 ng/µl, using nuclease-free water,
and stored at −20 ◦C until use. Bisulphite conversion
of DNA was carried out a EZ Methylation Kit (Zymo
Labs) according to the manufacturer’s protocol. Quan-
titation of converted bisulphite DNA and assessment
of completeness of conversion were carried out using
qRT–PCR, according to the method of Campan et al
[15], using primers specific for ALU repeats and
for 0% and 100% bisulphite conversion, against a
100% methylated DNA and 100% unmethylated DNA
reference.
Illumina methylation array analysis
Whole-genome methylation analysis was carried out
using the Illumina HumanMethylation27 array system.
1.1 µg tumour/adenoma/normal DNA was bisulphite-
converted according to the recommended protocol,
quantified and quality-checked as above. The converted
DNA was whole-genome amplified and hybridized to
the array, which was processed according to the manu-
facturer’s protocol. The arrays were then scanned using
the Illumina BeadArray system. Standard array qual-
ity checks were performed post-scanning, using Illu-
mina GenomeStudio software, and only samples that
passed internal QC were taken forward for analysis.
Raw probe data were exported from GenomeStudio
into R 2.9.0. The percentage methylation β (β, %methy-
lation) at each CpG island was calculated using the
internal proprietary algorithm and normalization car-
ried out initially using the IlluminaCustom model, and
with samples being divided into two groups, tumours
versus normals and adenomas versus normals. Probes
that failed quality control (detection p value> 0.05)
were removed, as well as all X chromosome probes,
due to hemi-methylation of these probes in female
patients.
Data were exported from GenomeStudio into R and
the data normalized successfully, using the normal-
izeMethyLumiSet function of methylumiR. A least-
squares linear fit model was performed on the methy-
lation dataset for each group. The model estimates
were then transformed into moderated t-statistics and
log-odds of differential expression by empirical Bayes
shrinkage of the standard errors towards a com-
mon value. For cancers and normals this was car-
ried out as a paired analysis, but for adenomas this
analysis was carried out in an unpaired fashion, as
no paired samples existed for adenomas and nor-
mals, reducing the power of the analysis. The top
100 probes based on the highest BF were identified
and QQ and volcano plots produced for the entire
probe set.
Hierarchical clustering (HC) of the datasets was
performed using the clustering function of MultiEx-
periment Viewer (TMEV), part of the TM4 Microar-
ray Software Suite [16]. GSEA was carried out using
GSEA v 2.1 [17] (Broad Institute, MIT, USA).











MSS c.35 G> A
(p.G12D)
WT WT WT
21 T MSS WT WT WT WT
22 T MSS c.35 G> A
(p.G12D)
WT WT WT
23 T MSS WT WT WT WT
24 T MSS WT WT WT WT
26 T MSS WT WT WT WT
27 T MSS WT WT WT WT
28 T MSS WT WT WT WT
29 T MSI WT WT WT c.1799 T>A
(p.V600E)
30 T MSS WT c.38 G> A (p.
G13D)
WT WT
Ad1 MSS WT WT WT WT
Ad2 MSS WT WT WT WT
Ad3 MSS WT WT WT WT
Ad4 MSI c.35 G> A
(p.G12D)
WT WT V600E
Ad5 MSS WT WT WT WT
KRAS, BRAF and MSI status
Mutation analysis of codons 12,13 and 146 of
KRAS and codon 600 of BRAF was carried out by
direct sequencing (details available on request). For
microsatellite instability (MSI) analysis, only the
BAT25 and BAT26 alleles were studied. Samples
were said to be MSI if they possessed one or more
additional alleles at either locus compared with a
control microsatellite-stable DNA. Results for KRAS ,
BRAF and MSI status are shown in Table 3.
Correlation between promoter methylation and
expression of genes
In order to ascertain whether observed differential
methylation changes correlated with changes in
expression of the gene, we used publically avail-
able datasets for methylation and expression from
Hinoue et al [12]. This dataset used the Illumina
HumanMethylation27 array to measure whole-genome
methylation (GEO Accession No. GSE25062) and
the Illumina Ref-8 whole-genome expression array to
measure expression (GEO Accession No. GSE25070).
Expression and methylation values were correlated
using linear regression.
Results
When comparing carcinomas and paired normal
tissue, we found that> 2000 genes were differentially
methylated at pcorrected < 0.05 (Figure 1a). Overall
results are shown in Tables S1–S3 (see Supplementary
material). On examining the volcano plots of each
cohort, a number of interesting features were found.
Comparing adenomas with normal tissue, the majority
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of genes did not change significantly or became
hypomethylated in the transition from normal tissue
to adenoma. In contrast, however, comparing normal
tissue with carcinoma, there was a shift towards
increased methylation in promoter regions in the latter,
an observation confirmed by the larger proportion
of genes that were methylated in carcinomas versus
adenomas. These results suggest that the bulk of
promoter methylation occurs around the time of
transition from colorectal adenoma to carcinoma.
The highest-rated individual gene for differential
methylation in carcinomas versus normals was GRASP
(padjusted = 1.59 × 10–5, BF = 12.62), which encodes
the general receptor for phosphoinositides-1-associated
scaffold protein. GRASP was also the highest-rated
gene when comparing adenomas and normal tissue
(padjusted = 1.68 × 10–6, BF = 14.53). The highest-rated
gene when comparing carcinomas versus adenomas
was ATM (padjusted = 2.0 × 10–4, BF = 10.17). Volcano
and QQ plots for each three groups of methylation
comparisons are shown in Figure 1a–c.
Comparison of methylation and expression for
GRASP was carried out using the dataset of Hinoue
et al [12]. This demonstrated a strong negative correla-
tion (coef logexprGRASP = −2.95, t = −2.66, p = 0.01), ie
promoter methylation of GRASP led to reduced expres-
sion. We found no correlation between ATM promoter
methylation and expression, in common with many
other studies showing that ATM expression may not
be controlled by methylation in the ATM promoter
[18–20].
Hierarchical clustering (HC) into CIMP groups
We studied the effectiveness of commonly-used CIMP
gene sets in ascertaining whether CIMP was a true
reflection of whole-genome methylation and whether
methylation patterns in our study segregated into
CIMP, as previously observed. CIMP genes were
defined, as those given in the studies of Toyota
[1], Yagi [10] and Weisenberger [21], as CACNA1G ,
CDKN2A, IGF2 , MLH1 , NEUROG1 , RUNX3 and
SOCS1 . Because of their position outside CpG islands
and lack of coverage on the HumanMethylation27
array, MINT-1 , MINT-2 and MINT-31 were not
included in the analysis. A median methylation value
(βmedian) was calculated for all the normal mucosa
samples in the dataset, and each βtumour value was
subtracted from this. Hierarchical clustering was then
performed on the samples, using a Pearson correlation
metric and average linkage clustering to generate a heat
map and clusters for the samples.
The heat map for clustering by CIMP probes is
shown in Figure 2 for carcinomas and adenomas. In
the cancer group, there appeared to be three distinct
clusters, with a low methylation cluster (cancers 28 T
and 29 T), an intermediate methylation cluster (24 T)
and a high methylation cluster (20 T, 22 T, 23 T, 26 T,
27 T and 30 T).
For the cancer samples, we initially compared our
clusters with the conventional definition of CIMP of
Weisenberger et al [21] and Toyota et al [1], viz.
that ≥ 3/5 CIMP-related genes should be methylated to
call a sample CIMP-H, a trait that is usually associated
with BRAF mutation. In our group of tumours, no
sample fitted this definition of CIMP-H using ab initio
hierarchical clustering. We observed that the CIMP-
intermediate phenotype observed by Yagi et al [10]
would correspond with the group of tumours that
clustered into a high methylation group seen in our
series. Within these cancers, 20 T and 22 T possessed
KRAS mutations, an association also observed by
Yagi in the CIMP-intermediate group. We also found
that in tumour 29 T, although it was BRAF mutant
and microsatellite unstable, there were low levels of
methylation, in contrast to other studies.
In the adenoma dataset, the pattern of hierarchical
clustering was clearer, with segregation into two main
clusters, one with high levels of methylation, which
fitted with the definition of CIMP-H by Weisenberger
and Toyota. There was one other cluster with lower
levels of methylation, conforming to the CIMP-L
epigenotype. In this dataset, the MSI+, BRAF -mutant
adenoma (Ad4) was not associated with high levels of
methylation (Ad1).
Gene set enrichment analysis (GSEA)
GSEA to determine sets of genes that tended to be
hypo/hypermethylated was performed for carcinomas
versus normal tissue and adenomas versus normal
tissue. The C5 GO gene set was chosen for the analysis,
which consists of 1454 curated gene sets divided
by molecular function. As more than one probe was
present for each CpG island, and because there may
have been multiple probes for each gene, probes for
the same gene were collapsed in the analysis, and 1000
GSEA iterations were carried out.
GSEA comparing carcinomas versus normal tissue
In total, 569/938 gene sets were hypermethylated and
369 gene sets were hypomethylated. The top 10 hyper-
methylated sets (by normalized enrichment score, NES)
are shown in Table S4 (see Supplementary material).
The overall false-discovery rate (FDR) statistic was
0.31, missing the threshold for significance set by
Subramanian et al [17] of FDR< 0.25. One gene set
was significantly enriched at p< 0.01 (FDR = 0.24) and
11 gene sets were significantly enriched at p< 0.05
(FDR = 0.31). The top-ranked gene set was the extra-
cellular matrix structural constituent gene set and the
top-ranked gene within this was FBN2 (Fibrillin-2),
which has been proposed previously as a marker for
tumour methylation by Yagi et al [10]. Within the
third-ranked gene set, the GRM series of metabotropic
glutamate receptors was highly ranked, a set of genes
which has been identified as being associated with
altered responses to 5-FU chemotherapy [22].
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Figure 1. QQ and volcano plots of Bayesian analyses of differential methylation for cancers versus normal samples (a), adenomas versus
normal samples (b) and cancers versus adenomas (c). The QQ plots (left) demonstrate probes that are hypermethylated (above the black
normal distribution line on the left of the plot) and hypomethylated (below the normal line on the left of the plot). The volcano plot (right)
demonstrates that both significantly hypomethylated and hypermethylated probes exist when comparing cancers with normal tissues, The
top five probe identifiers are shown in blue text on the volcano plots, and that the five most significantly differentially methylated probes
all become hypermethylated.
A leading-edge analysis was then carried out in
GSEA (leading-edge plots in Figures S1 and S2;
see Supplementary material) and the top 20 datasets
ranked by NES were chosen. The top-ranked gene in
the leading-edge analysis was SLIT2 (slit homologue
2), appearing in six gene sets. SLIT2 interacts with
netrin-1 (also known as Deleted in Colorectal Can-
cer), a possible tumour suppressor [23] that has pre-
viously been identified in other methylation studies of
CRC [11]. Other genes of interest in CRC seen in
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Figure 2. Hierarchical clustering diagram of CIMP probes for cancers and adenomas. In cancers (left) there is clustering into two groups,
which correspond to the CIMP-intermediate and CIMP-low groups previously described by Yagi et al [10]. In the adenomas (right)
there is clustering into two groups, with a single sample (Ad1) having extensive methylation compatible with CIMP and another group
demonstrating low levels of methylation: red, hypermethylation; green, hypomethylation; black, no change.
the leading-edge analysis included SLIT1 , TGFBR2 ,
PAX2 , UNC5C , OTX2 , NGNT1 and GDNF1 .
GSEA comparing adenomas and normal tissue
GSEA was then carried out comparing adenomas with
normal mucosa. 118/938 gene sets were hypermethy-
lated and 118/938 became hypermethylated, with no
gene sets meeting the FDR< 25% threshold. How-
ever, 21 hypomethylated gene sets were significantly
enriched at p< 0.01 and 98 were enriched at p < 0.05.
The top 20 sets are shown in Table S5 (see Supplemen-
tary material). In these sets, the top-ranked set was
Viral Genome Replication, a set that includes UBP1
and EIF5A (eukaryotic translation initiation factor 5A).
The 98 significantly enriched gene sets were then
taken forward into a leading-edge analysis to identify
common genes that were hypomethylated. The genes
of interest within this subset included the top-rated
NDUFA13 (NADH dehydrogenase ubiquinone 1α sub-
complex subunit 13), represented in 20 gene sets. This
gene has been shown to interact with STAT5 [24] and
therefore the JAK–STAT–EGFR pathway, which has
been associated with a worse prognosis in CRC [25].
Discussion
We have carried out whole-genome methylation analy-
sis of paired colorectal tumour and normal tissues, and
have undertaken a comparison with unpaired colorec-
tal adenomas. A strength of our study was the use of
paired tumour–normal mucosa as well as premalignant
adenomas. Our study suffers from small sample num-
bers, due to the difficulties of obtaining this type of
material, and therefore introduces potential bias. Our
study also focused solely on human tumour material,
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and did not take account of the tumour microenviron-
ment (ie tumour-associated fibroblasts), as described
by Allen et al [26]. This microenvironment could have
modulatory effects on tumour behaviour in addition to
promoter methylation and could also contaminate any
methylation analysis.
Using Bayesian analysis, we found a strong evi-
dence of GRASP promoter methylation in carci-
nomas and adenomas. We have also shown that
GRASP promoter methylation is significantly corre-
lated with GRASP expression. As we found that
GRASP becomes methylated in both adenomas and
carcinomas, it is reasonable to assume that its pro-
moter methylation occurs at an early stage in the
adenoma–carcinoma sequence. GRASP is located at
chromosome 12q13.13 and encodes a 395 amono acid
protein involved in p14ARF signalling [27]. The nor-
mal function of GRASP is to promote ARF –Rac sig-
nalling. p14ARF, which is encoded by the CDKN2A
(INK4a) tumour suppressor gene, acts as a checkpoint
within the ARF–MDM2–p53 pathway [28], in that
normal expression of p14ARF is required to activate
and stabilize p53, which can interrupt the cell cycle if
needed when a mutagenic event occurs [29], as shown
in Figure S3 (see Supplementary material). We also
found that the promoter region of ATM is significantly
methylated in the transition from adenoma to carci-
noma; however, this does not correlate with expression
of ATM. Not all gene promoter regions control expres-
sion of that gene and it is possible that control of
expression of ATM is via another mechanism, given
the heterogeneity of data [18–20] comparing ATM pro-
moter methylation and expression.
We found that the bulk of promoter methylation
occurs in the transition from adenoma to carcinoma,
rather than in that from normal tissue to adenoma.
Moreover, hypomethylation occurs in the transition
from normal tissue to adenoma, whereas hypermethy-
lation is mostly associated with the transition from ade-
noma to carcinoma. A few other studies have examined
the temporal relationship of promoter methylation to
colorectal carcinogenesis, but these have mainly exam-
ined CIMP genes. For example, Ahlquist et al [30]
examined the methylation of a set of 11 genes made
up of a mixture of CIMP genes and others identified as
significant in methylation studies. They found that the
average number of methylated genes was 0.4 in normal
mucosa, but 2.2 in adenomas and 3.9 in carcinomas.
They suggested that the bulk of methylation occurs
during adenoma formation. However, our cluster data
suggest that CIMP is not fully representative of whole-
genome methylation. None of the cancers in this study
reached the conventional threshold for CIMP positivity
[21], although we did observe the reported association
between KRAS mutation and a ’CIMP-low’ phenotype
[10]. We also agreed with the findings of Yamauchi
et al [13], as all our cecal tumours possessed KRAS
mutations, with variable levels of methylation.
One of the main roles of GSEA is that it can
highlight groups of biological pathways for further
investigation. For example, in the GSEA for the
normal–carcinoma group, cellular pathways concerned
with signalling (cAMP, tyrosine kinase and G-protein-
coupled receptors) were significantly enriched in the
tumours. The metabotropic glutamate receptors (GRM)
were significantly over-represented in the GSEA anal-
ysis, and these have been implicated in chemotherapy
resistance in a number of tumours, including CRC [22],
melanoma [31] and glioblastoma [32]. The leading-
edge analysis of the CRC methylation dataset revealed
that extensive methylation occurs in the DCC–netrin
pathway. SLIT2 (SLIT2 homologue 2 protein), as well
as UNC5C , are methylated in the CRC samples in this
study. SLIT2 has been shown to be a negative regula-
tory component of the DCC –netrin pathway [33], and
normal expression of SLIT2 has been shown to repress
growth and metastasis of squamous cell carcinomas
and fibrosarcomas [23].
In conclusion, the use of whole-genome methyla-
tion analysis has highlighted a number of genes and
pathways, some of which have not been suggested to
have a role in CRC. GRASP is one such interesting
candidate. We have also demonstrated that promoter
methylation occurs mainly in the transition from ade-
noma to carcinoma, suggesting that epigenetic events
may be more important in promoting than initiating
colorectal tumorigenesis.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article.
Figure S1. Leading edge diagram for carcinoma versus normal tissue, demonstrating the number of times a gene has a significant change in
methylation in each set. SLIT2 , the highest-ranked gene, is noted to be significantly hypermethylated in six different gene sets.
Figure S2. Leading edge diagram of adenoma versus normal tissue, demonstrating the number of times a gene is significantly hypomethylated
within a gene set. The top-ranked gene, NDUFA13 , occurs in 20 different gene sets.
Figure S3. Representation of GRASP/CDKN2A (p14ARF)/TP53 pathway.
Table S1. Top 25 differentially methylated genes from Bayesian model of carcinomas versus normal tissue.
Table S2. Top 25 differentially methylated genes from Bayesian model of adenomas versus normal tissue.
Table S3. Top 25 differentially methylated genes from Bayesian model of carcinomas versus adenomas.
Table S4. Table of gene set ranked by NES score for cancers versus normals in methylated probes.
Table S5. Table of gene sets in adenomas ranked by NES score for adenomas versus normals in demethylated probes.
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